The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
In the rituximab era, one-third of diffuse large B-cell lymphoma (DLBCL) patients experience relapse/refractory disease after first-line anthracycline-based immunochemotherapy (IChemo). Optimal management remains an unmet medical need. The aim of this study was to report the outcomes of a cohort of refractory patients according to their patterns of refractoriness and the type of salvage option. The investigators performed a retrospective analysis, which included 104 DLBCL patients treated at Lyon Sud University Hospital (2002-2017) who presented with refractory disease. The investigators retrospectively evaluated the outcomes of a cohort of 104 refractory patients according to their patterns of refractoriness and the type of salvage option.
Outcome according to pattern of refractoriness [ Time Frame: Up to 4 years ]
OS was defined as the time from first relapse, or progression, to death from any cause.
Secondary Outcome Measures :
Outcome according to pattern of refractoriness [ Time Frame: Up tp 24 months ]
EFS was defined as the time from first relapse, or progression, to the next event (defined as either second relapse/progression, change of therapy, or death from any cause). Patients who did not experience an event were censored at the last follow-up.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Man or woman diagnosed for a DLBCL from January 2002 to January 2017
-≥18 years of age
diagnosed with DLBCL at Lyon Sud University Hospital (LSUH) from January 2002 to January 2017
presented with refractory disease in response to front-line therapies
including anthracycline-based chemo and a monoclonal anti-CD20 antibody
Patients with a history of indolent lymphoma,
Patients with a primary central nervous system (CNS) lymphoma or immunosuppression-related lymphoma